Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe

Author(s): Milcah Dhoro, Bernard Ngara, Gerald Kadzirange, Charles Nhachi, Collen Masimirembwa

Journal Name: Current HIV Research
HIV and Viral Immune Diseases

Volume 11 , Issue 6 , 2013

Become EABM
Become Reviewer
Call for Editor


A study was conducted in an HIV/AIDS Zimbabwean cohort to assess possible associations of pharmacogenetic variants with common adverse drug reactions (ADRs) during anti-retroviral treatment (ART) and/or tuberculosis (TB) treatment. Genotype and allele frequencies for CYP2B6 G516T, CYP2B6 T983C, CYP2A6*17, ABCB1 rs10276036 C>T, NAT2*5 and NAT2*14 were similar to those reported in literature for other African populations. The CYP2B6 516TT genotype and male gender were significantly associated with occurrence of Efavirenz induced central nervous system disorders (OR 20.58, p=0.004) and the ABCB1 rs10276036TT genotype with Nevirapine induced skin hypersensitivity (OR 4.01, p=0.04). For Stavudine, time on treatment was the main factor in development of lipodystrophy (OR 1.06, p<0.0001). For isoniazid, increasing patient age was associated with peripheral neuropathy (OR 1.05, p=0.001). Although genetic polymorphisms may play a role in predicting occurrence of ADRs, this study also indicates that other factors (gender, age, treatment time) are crucial in predicting drug-induced adverse effects.

Keywords: Antiretroviral treatment, adverse drug reactions, genetic polymorphisms, HIV/AIDS.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 03 September, 2013
Page: [481 - 490]
Pages: 10
DOI: 10.2174/1570162X113119990048
Price: $65

Article Metrics

PDF: 55